OBJECTIVES: Laser treatment of benign prostatic hyperplasia has been introduced. The thulium:YAG (Tm:YAG) laser combines the advantages of established laser systems. This study reports the preliminary results of vaporesection of the prostate, using this 2-microm continuous wave (cw) laser. MATERIAL AND METHODS: A total of 54 consecutive patients were treated with the Tm:YAG laser. The outcomes measured were resection time, catheter time, improvement in urinary flow rate (Q(max)), and post-voiding residual urine (PVR). International Prostate Symptom Score (IPSS) and Quality of Life Index (QoL) were recorded. RESULTS: The mean age was 61 years. Mean prostate volume was 30.3 cc. Average resection time was 52 min. Catheter time was 1.7 days. Qmax significantly improved from 4.2 to 20.9 ml on average. PVR decreased from 86 to 16 ml. IPSS and QoL score improved from 19.8 to 6.5 and 4 to 1, respectively. No patient required re-hospitalization. Transfusions were not necessary. CONCLUSIONS: These preliminary results indicate that Tm:YAG vaporesection of the prostate is safe and efficient. The 18-month follow-up data showed major improvement in voiding symptoms and QoL. Longer follow-up is needed to prove durability of these promising results.
OBJECTIVES: Laser treatment of benign prostatic hyperplasia has been introduced. The thulium:YAG (Tm:YAG) laser combines the advantages of established laser systems. This study reports the preliminary results of vaporesection of the prostate, using this 2-microm continuous wave (cw) laser. MATERIAL AND METHODS: A total of 54 consecutive patients were treated with the Tm:YAG laser. The outcomes measured were resection time, catheter time, improvement in urinary flow rate (Q(max)), and post-voiding residual urine (PVR). International Prostate Symptom Score (IPSS) and Quality of Life Index (QoL) were recorded. RESULTS: The mean age was 61 years. Mean prostate volume was 30.3 cc. Average resection time was 52 min. Catheter time was 1.7 days. Qmax significantly improved from 4.2 to 20.9 ml on average. PVR decreased from 86 to 16 ml. IPSS and QoL score improved from 19.8 to 6.5 and 4 to 1, respectively. No patient required re-hospitalization. Transfusions were not necessary. CONCLUSIONS: These preliminary results indicate that Tm:YAG vaporesection of the prostate is safe and efficient. The 18-month follow-up data showed major improvement in voiding symptoms and QoL. Longer follow-up is needed to prove durability of these promising results.
Authors: N P Roos; J E Wennberg; D J Malenka; E S Fisher; K McPherson; T F Andersen; M M Cohen; E Ramsey Journal: N Engl J Med Date: 1989-04-27 Impact factor: 91.245
Authors: Jaspreet S Sandhu; Casey Ng; Brian A Vanderbrink; Celeste Egan; Steven A Kaplan; Alexis E Te Journal: Urology Date: 2004-12 Impact factor: 2.649
Authors: Ramsay L Kuo; Samuel C Kim; James E Lingeman; Ryan F Paterson; Stephanie L Watkins; Garrick R Simmons; Ronald E Steele Journal: J Urol Date: 2003-07 Impact factor: 7.450
Authors: Piotr Paweł Świniarski; Stanisław Stępień; Waldemar Dudzic; Stanisław Kęsy; Mariusz Blewniewski; Waldemar Różański Journal: Cent European J Urol Date: 2012-09-04